ReviewOncology letters2026
Psychological stress and tumor progression: Molecular mechanisms and therapeutic implications (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychological stress contributes to tumor progression through a number of biological pathways. Activation of the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system induces the release of stress-related mediators, including catecholamines and glucocorticoids, which regulate tumor development and metastasis. The present review summarizes the molecular mechanisms underlying stress-mediated cancer progression at the cellular, immune and neural levels. At the cellular level, stress hormones modulate tumor cell proliferation, autophagy, metabolic reprogramming and stemness maintenance through signaling pathways such as dopamine receptor D2 (DRD2)/ERK/β-catenin and β2-adrenergic receptor/cyclic adenosine monophosphate (cAMP)/protein kinase A/cAMP-response element-binding protein. Within the tumor microenvironment, psychological stress promotes the accumulation of myeloid-derived suppressor cells, induces T-cell exhaustion, facilitates M2 macrophage polarization and enhances angiogenesis and lymphatic remodeling, collectively contributing to an immunosuppressive microenvironment. In addition, sympathetic, parasympathetic and sensory neurons directly regulate tumor cell behavior through pseudosynaptic interactions and neurotransmitter release, including glutamate, acetylcholine and norepinephrine, thereby establishing a neuro-immune-tumor regulatory network. Based on these mechanisms, emerging therapeutic strategies, including β-blockers, inhibitors targeting DRD2, lactate dehydrogenase A and G protein-coupled receptor kinase 3, neuromodulation approaches and psychosocial interventions, have demonstrated potential therapeutic value in preclinical and clinical studies. The present review systematically summarizes the complex molecular pathways associating psychological stress to tumor progression. Despite notable advances, challenges remain in understanding tumor-specific heterogeneity in stress signaling pathways and the spatiotemporal regulation of neuro-immune-tumor interactions. Future studies focusing on multimodal combination strategies may provide novel insights for integrating stress management into comprehensive cancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.